Program
telitacicept
Also written as “Telitacicept”, “RC18 160mg” and “RC18 240mg”.
Its studies are mostly in Lupus Erythematosus, Systemic · Glomerulonephritis, IGA · Myasthenia Gravis · Sjogren's Syndrome · Lymphoma, Follicular, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| RemeGen | 194 open or running | phase 3since Jan 8, 2017 | Aug 24, 2016 | Dec 31, 2026phase 3 · NCT07249632 |
| Vor Biopharma | 42 open or running | phase 3since Mar 23, 2022 | Mar 23, 2022 | Mar 2027phase 3 · NCT06456580 |
| Innovent Biologics | 22 open or running | phase 2since Sep 13, 2026 | Sep 13, 2026 | Jan 31, 2027phase 1 · NCT07886476 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Aug 24, 2016.
- May 21, 2021Phase 2 study in Glomerulonephritis, IGARemeGen · NCT04905212 · 15 enrolled · United States
- Jan 26, 2022Phase 1 study in Lupus Erythematosus, SystemicRemeGen · NCT05247203 · 92 enrolled · China
- Mar 23, 2022Vor Biopharma's first study: phase 3 study in Lupus Erythematosus, SystemicNew to Vor BiopharmaVor Biopharma · NCT05306574 · 91 enrolled · United States, Argentina, Australia and more
- Dec 26, 2022Phase 2 study in Lupus NephritisRemeGen · NCT05680480 · 120 planned · China
- Dec 29, 2022Phase 3 study in Primary Sjogren's SyndromeRemeGen · NCT05673993 · 381 enrolled · China
- Jan 8, 2023Phase 1 study in Lupus Erythematosus, SystemicRemeGen · NCT05687526 · 16 enrolled · China
- Feb 12, 2023Phase 3 study in Myasthenia GravisRemeGen · NCT05737160 · 114 enrolled · China
- Mar 5, 2023Phase 3 study in Glomerulonephritis, IGARemeGen · NCT05799287 · 318 enrolled · China
- Jun 7, 20242 phase 3 studiesVor Biopharma · NCT06456580, NCT06456567
- Nov 18, 2025Phase 3 study in Myasthenia GravisRemeGen · NCT07249632 · 120 planned · China
- Feb 4, 2026Phase 3 study in Sjogren's SyndromeVor Biopharma · NCT07404865 · 250 planned · United States, Georgia
- Mar 9, 2026Phase 3 study in CTD-ILDRemeGen · NCT07495033 · 260 planned · China
- Sep 13, 2026Innovent Biologics's first study: phase 2 study in Sjogren's SyndromeNew to Innovent BiologicsInnovent Biologics · NCT07836660 · 198 planned · China
- Oct 8, 2026Phase 1 study in Glomerulonephritis, IGAInnovent Biologics · NCT07886476 · 100 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Myasthenia GravisRemeGen · NCT07249632
- Jan 31, 2027Primary completion: phase 1 study in Glomerulonephritis, IGAInnovent Biologics · NCT07886476
- Mar 2027Primary completion: phase 3 study in Myasthenia GravisVor Biopharma · NCT06456580
- Nov 1, 2027Primary completion: phase 2 study in Sjogren's SyndromeInnovent Biologics · NCT07836660
TargetBeta
“A fusion protein composed of the extracellular domain of human tumor necrosis factor receptor superfamily member 13B (TNFRSF13B; transmembrane activator and calcium modulator and cyclophilin ligand interactor; TACI) ”NCIt, by rule
Other programs on TNFRSF13B
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| povetaciceptrule | Vertex Pharmaceuticals | phase 3 | 9 |
| SHR-2173 | Jiangsu HengRui Medicine | phase 2 | 8 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07886476Glomerulonephritis, IGA · China | 1 | Not yet recruiting | Innovent Biologics | Jan 31, 2027 | 100 |
| NCT07836660Sjogren's Syndrome · China | 2 | Not yet recruiting | Innovent Biologics | Nov 1, 2027 | 198 |
| NCT07495033CTD-ILD · China | 3 | Not yet recruiting | RemeGen | May 31, 2029 | 260 |
| NCT07404865Sjogren's Syndrome · United States, Georgia | 3 | Recruiting | Vor Biopharma | Dec 2028 | 250 |
| NCT07249632Myasthenia Gravis · China | 3 | Recruiting | RemeGen | Dec 31, 2026 | 120 |
| NCT06456580Myasthenia Gravis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Vor Biopharma | Mar 2027 | 191 |
| NCT06456567Lupus Erythematosus, Systemic · United States | 3 | Withdrawn | Vor Biopharma | Jan 2, 2025 | 0 |
| NCT05799287Glomerulonephritis, IGA · China | 3 | Active, not recruiting | RemeGen | Jun 2026 | 318 |
| NCT05737160Myasthenia Gravis · China | 3 | Completed | RemeGen | Nov 26, 2024 | 114 |
| NCT05687526Lupus Erythematosus, Systemic · China | 1 | Completed | RemeGen | Nov 14, 2025 | 16 |
| NCT05673993Primary Sjogren's Syndrome · China | 3 | Completed | RemeGen | Oct 29, 2024 | 381 |
| NCT05680480Lupus Nephritis · China | 2 | Recruiting | RemeGen | Dec 2025 | 120 |
| NCT05306574Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 3 | Terminated | Vor Biopharma | Jan 6, 2025 | 91 |
| NCT05247203Lupus Erythematosus, Systemic · China | 1 | Completed | RemeGen | Oct 25, 2023 | 92 |
| NCT04905212Glomerulonephritis, IGA · United States | 2 | Terminated | RemeGen | Nov 9, 2023 | 15 |
| NCT04625153Multiple Sclerosis, Relapsing-Remitting · China | 2 | Terminated | RemeGen | Apr 3, 2026 | 8 |
| NCT04302103Systemic Myasthenia Gravis · China | 2 | Completed | RemeGen | Jan 14, 2022 | 29 |
| NCT04291781Glomerulonephritis, IGA · China | 2 | Completed | RemeGen | May 20, 2021 | 44 |
| NCT04235933Healthy · China | 1 | Completed | RemeGen | Dec 20, 2019 | 36 |
| NCT04082416Lupus Erythematosus, Systemic · China | 3 | Completed | RemeGen | Apr 24, 2022 | 335 |
| NCT04078386Primary Sjögren's Syndrome · China | 2 | Completed | RemeGen | Jun 23, 2021 | 42 |
| NCT03330418Neuromyelitis Optica · China | 3 | Terminated | RemeGen | Apr 3, 2026 | 178 |
| NCT03016013Lymphoma, Follicular · China | 3 | Completed | RemeGen | Nov 19, 2022 | 479 |
| NCT02885610Lupus Erythematosus, Systemic · China | 2 | Completed | RemeGen | Jun 11, 2019 | 249 |
| NCT02882087Lymphoma, Follicular · China | 2 | Terminated | RemeGen | Feb 25, 2019 | 60 |
How it is read
Names in the registry
- “Telitacicept”, 11 entries
- “RC18 160mg”, 3 entries
- “RC18 240mg”, 3 entries
- “RC18 240 mg”, 2 entries
- “RC18 160 mg”, 2 entries
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 6 studies
- Glomerulonephritis, IGA, 4 studies
- Myasthenia Gravis, 4 studies
- Sjogren's Syndrome, 3 studies
- Lymphoma, Follicular, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.